155 related articles for article (PubMed ID: 22062222)
1. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma.
Kitaba S; Murota H; Terao M; Azukizawa H; Terabe F; Shima Y; Fujimoto M; Tanaka T; Naka T; Kishimoto T; Katayama I
Am J Pathol; 2012 Jan; 180(1):165-76. PubMed ID: 22062222
[TBL] [Abstract][Full Text] [Related]
2. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
Clin Immunol; 2002 Jan; 102(1):77-83. PubMed ID: 11781070
[TBL] [Abstract][Full Text] [Related]
3. Role of Rac1 in a bleomycin-induced scleroderma model using fibroblast-specific Rac1-knockout mice.
Liu S; Kapoor M; Shi-wen X; Kennedy L; Denton CP; Glogauer M; Abraham DJ; Leask A
Arthritis Rheum; 2008 Jul; 58(7):2189-95. PubMed ID: 18576327
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of skin sclerosis by 15deoxy delta12,14-prostaglandin J2 and retrovirally transfected prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma.
Kohno S; Endo H; Hashimoto A; Hayashi I; Murakami Y; Kitasato H; Kojima F; Kawai S; Kondo H
Biomed Pharmacother; 2006 Jan; 60(1):18-25. PubMed ID: 16337105
[TBL] [Abstract][Full Text] [Related]
5. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model.
Liu S; Kapoor M; Denton CP; Abraham DJ; Leask A
Arthritis Rheum; 2009 Sep; 60(9):2817-21. PubMed ID: 19714619
[TBL] [Abstract][Full Text] [Related]
6. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.
Kapoor M; McCann M; Liu S; Huh K; Denton CP; Abraham DJ; Leask A
Arthritis Rheum; 2009 Sep; 60(9):2822-9. PubMed ID: 19714649
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of etanercept in bleomycin-induced experimental scleroderma.
Koca SS; Isik A; Ozercan IH; Ustundag B; Evren B; Metin K
Rheumatology (Oxford); 2008 Feb; 47(2):172-5. PubMed ID: 18174229
[TBL] [Abstract][Full Text] [Related]
8. Investigation of sensory neurogenic components in a bleomycin-induced scleroderma model using transient receptor potential vanilloid 1 receptor- and calcitonin gene-related peptide-knockout mice.
Szabó A; Czirják L; Sándor Z; Helyes Z; László T; Elekes K; Czömpöly T; Starr A; Brain S; Szolcsányi J; Pintér E
Arthritis Rheum; 2008 Jan; 58(1):292-301. PubMed ID: 18163477
[TBL] [Abstract][Full Text] [Related]
9. Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.
Akashi K; Saegusa J; Sendo S; Nishimura K; Okano T; Yagi K; Yanagisawa M; Emoto N; Morinobu A
Arthritis Res Ther; 2016 May; 18(1):113. PubMed ID: 27209208
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma.
Ozgen M; Koca SS; Dagli AF; Gundogdu B; Ustundag B; Isik A
Clin Exp Dermatol; 2012 Jan; 37(1):48-54. PubMed ID: 22182434
[TBL] [Abstract][Full Text] [Related]
11. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice.
Yamamoto T; Takahashi Y; Takagawa S; Katayama I; Nishioka K
J Rheumatol; 1999 Dec; 26(12):2628-34. PubMed ID: 10606374
[TBL] [Abstract][Full Text] [Related]
12. Ghrelin prevents the development of dermal fibrosis in bleomycin-induced scleroderma.
Koca SS; Ozgen M; Sarikaya M; Dagli F; Ustundag B; Isik A
Clin Exp Dermatol; 2014 Mar; 39(2):176-81. PubMed ID: 24033834
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.
Matsushita M; Yamamoto T; Nishioka K
Int Arch Allergy Immunol; 2004 Dec; 135(4):348-56. PubMed ID: 15564778
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice.
Tomiyama-Hanayama M; Rakugi H; Kohara M; Mima T; Adachi Y; Ohishi M; Katsuya T; Hoshida Y; Aozasa K; Ogihara T; Nishimoto N
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F679-84. PubMed ID: 19570877
[TBL] [Abstract][Full Text] [Related]
15. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma.
Yamamoto T; Takagawa S; Katayama I; Nishioka K
Clin Immunol; 1999 Jul; 92(1):6-13. PubMed ID: 10413648
[TBL] [Abstract][Full Text] [Related]
16. A CD40-CD154 interaction in tissue fibrosis.
Kawai M; Masuda A; Kuwana M
Arthritis Rheum; 2008 Nov; 58(11):3562-73. PubMed ID: 18975310
[TBL] [Abstract][Full Text] [Related]
17. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma.
Yamamoto T; Takagawa S; Katayama I; Yamazaki K; Hamazaki Y; Shinkai H; Nishioka K
J Invest Dermatol; 1999 Apr; 112(4):456-62. PubMed ID: 10201529
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma.
Wu MH; Yokozeki H; Takagawa S; Yamamoto T; Satoh T; Kaneda Y; Katayama I; Nishioka K
Gene Ther; 2004 Jan; 11(2):170-80. PubMed ID: 14712301
[TBL] [Abstract][Full Text] [Related]
19. Bleomycin-induced pulmonary fibrosis is independent of eosinophils.
Hao H; Cohen DA; Jennings CD; Bryson JS; Kaplan AM
J Leukoc Biol; 2000 Oct; 68(4):515-21. PubMed ID: 11037973
[TBL] [Abstract][Full Text] [Related]
20. Effects of oligoelements Se, Zn, and Mn plus Lachesis muta venom in experimental scleroderma.
Crescenti EJ; Medina VA; Sambuco LA; Cremaschi GA; Genaro AM; Cricco GP; Martín GA; Valli E; Martinel Lamas DJ; Perazzo JC; Rivera ES; Bergoc RM
Biol Trace Elem Res; 2014 Feb; 157(2):138-46. PubMed ID: 24363240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
